SAN DIEGO, June 20, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR) /bupropion SR) clinical data presentations taking place at the American Diabetes Association (ADA) 73rd Scientific Sessions, June 21-25, 2013.
ADA: McCormick Place Convention Center (West Building), Chicago, IL
Abstract# 1056-P "Combination Naltrexone/Bupropion Therapy Resulted in Clinically Meaningful Improvements in Weight and Quality of Life - Integrated Analysis of Four Phase 3 Trials"
Lead Author: Ronette L. Kolotkin
Abstract# 1130-P "An Integrated Analysis of Weight Loss with Combination Naltrexone/Bupropion Therapy by BMI (Obesity) Classification"
Lead Author: Caroline M. Apovian
Abstract# 1149-P "Early Improvement in Control of Eating Is Associated with Long-term Weight Loss - Integrated Analysis of Four Phase 3 Trials of Combination Naltrexone/Bupropion Treatment"
Lead Author: Ken Fujioka
All abstracts will be presented at General Poster Session 2, on Sunday, June 23, from 12:00 PM - 2:00 PM, in Hall F1 Posters.
Abstract #1056-P will also be showcased in a Guided Audio Poster Tour at the Innovative Oral AgentsInnovative Discoveries session on Monday, June 24, from 1:00 PM - 2:00 PM.
About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.
VP, Corporate Communications and Business Development
SOURCE Orexigen Therapeutics, Inc.